Nanoparticle Vaccine Against Cancer

Researchers from UT Southwestern Medical Center have developed a first-of-its-kind nanoparticle vaccine immunotherapy that targets several different cancer types.

The nanovaccine consists of tumor antigens tumor proteins that can be recognized by the immune system – inside a synthetic polymer nanoparticle. Nanoparticle vaccines deliver minuscule particulates that stimulate the immune system to mount an immune response. The goal is to help people’s own bodies fight cancer.


cancer-cells-

What is unique about our design is the simplicity of the single-polymer composition that can precisely deliver tumor antigens to immune cells while stimulating innate immunity. These actions result in safe and robust production of tumor-specific T cells that kill cancer cells,” said Dr. Jinming Gao, a Professor of Pharmacology and Otolaryngology in UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center.

A study outlining this research, published online today in Nature Nanotechnology, reported that the nanovaccine had anti-tumor efficacy in multiple tumor types in mice.

The research was a collaboration between the laboratories of study senior authors Dr. Gao and Dr. Zhijian “James” Chen, Professor of Molecular Biology and Director of the Center for Inflammation Research. The Center was established in 2015 to study how the body senses infection and to develop approaches to exploit this knowledge to create new treatments for infection, immune disorders, and autoimmunity.

Source: http://www.utsouthwestern.edu/

How Anthrax Toxin Kills Tumors

Over the past decades, researchers have become particularly interested in the idea of hijacking the cell-killing capacity of bacterial toxins to target tumor cells. So far, engineered toxins from Pseudomonas, anthrax toxin, and ricin showed promising results in treating tumors in mice. But the mechanism of action of these toxins remains elusive. Now a new study in the journal Proceedings of the National Academy of Science sheds light on tumor proteins used by Bacillus anthracis to kill tumors.

anthrax-tumorModified anthrax toxin specifically targets the tumor vasculature to exert anti-tumor effects

As we worked more and more on anthrax toxin, we discovered, along with others, features of it that made it attractive as another bacterial protein toxin that could be redirected for curing cancer,” said Stephen Leppla from the National Institute of Allergy and Infectious Disease, senior author of the study.

Anthrax toxin has three sub-components that assemble within host cells before exerting their toxicity. PA, the cell-binding component of anthrax toxin, interacts with two cell surface proteins: tumor endothelium-marker 8 (TEM8) and capillary morphogenesis protein-2 (CMG2).

Finding that anthrax toxin specifically acts on tumor vasculature is particularly promising, given the stability of tumor endothelial cells compared to mutation-prone stromal cells. Anthrax toxin could thus be used to treat widely different tumors. “We would like to get to phase I human trials,” said Leppla. “We have collaborators who are testing our reagents in both cats and dogs who also get cancer but don’t have good treatment options. We’re hoping that this will provide further evidence that these reagents are effective.

Source: http://www.biotechniques.com/